The company intends to leverage and capitalise on the recent maturation of AI technology in developing its proprietary drug discovery platform
Peptris Technologies, a Bangalore-based AI drug discovery company, has announced $1M in pre seed round investment led by Speciale Invest. This strategic funding marks a pivotal step in boosting Peptris’ efforts in advancing AI-driven solutions in the drug development/discovery sector, with a special focus on developing novel therapies for undruggable targets, particularly in oncology, inflammation, and rare diseases.
Peptris is revolutionising drug discovery through the implementation of its AI platform. It is transforming the traditionally lengthy and costly drug discovery process, which often spans over a decade and incurs substantial costs, making essential medications financially out of reach for many. This technology efficiently narrows down extensive chemical libraries to pinpoint promising drug candidates, marking a significant advancement over traditional drug discovery methods.
The company intends to leverage and capitalise on the recent maturation of AI technology in developing its proprietary drug discovery platform.
Narayanan Venkatasubramanian, CEO and Co-founder, Peptris said, “We are thrilled to announce that we have secured investment from Speciale Invest. We are particularly impressed by their breadth of investment in the deep tech sector, which reflects a profound understanding and commitment to driving technological advancements. This partnership marks a significant milestone in our journey. The current funding will help us accelerate our AI-powered discovery programs and create a robust pipeline of potential drug candidates.”
“The backing from Speciale Invest is set to catalyse Peptris’ journey, supporting the expansion of the drug pipeline and further refinement of the platform. This funding isn’t just an investment in technology; it’s an investment in the future of healthcare in India, bringing hope of more accessible and affordable treatments to millions,” Venkat further added.
- Advertisement -